Neo ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) Study
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Neoplasms, Breast
Interventions: DRUG: Lapatinib|BIOLOGICAL: Trastuzumab|DRUG: Paclitaxel
Sponsor: Novartis Pharmaceuticals
Collaborators: Breast International Group|SOLTI Breast Cancer Research Group